Edition:
India

Kalvista Pharmaceuticals Inc (KALV.OQ)

KALV.OQ on NASDAQ Stock Exchange Global Market

19.25USD
4 Dec 2020
Change (% chg)

$0.72 (+3.89%)
Prev Close
$18.53
Open
$18.60
Day's High
$19.80
Day's Low
$18.50
Volume
24,491
Avg. Vol
27,616
52-wk High
$20.01
52-wk Low
$5.65

Latest Key Developments (Source: Significant Developments)

KalVista Pharmaceuticals Posts Q3 Revenue Of $1.6 Mln
Tuesday, 10 Mar 2020 

March 10 (Reuters) - Kalvista Pharmaceuticals Inc ::Q3 NET LOSS -9.3 MILLION USD VERSUS -4.0 MILLION USD LOSS YEAR AGO.Q3 REVENUE 1.6 MILLION USD VERSUS 3.9 MILLION USD YEAR AGO.Q3 DILUTED EPS LOSS 0.52 USD VERSUS 0.23 USD LOSS YEAR AGO.KALVISTA PHARMACEUTICALS - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $80.6 MILLION AS OF JANUARY 31, 2020.  Full Article

Kalvista Pharmaceuticals Reports Phase 2 Clinical Trial Results In Patients With Diabetic Macular Edema
Monday, 9 Dec 2019 

Dec 9 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS REPORTS PHASE 2 CLINICAL TRIAL RESULTS IN PATIENTS WITH DIABETIC MACULAR EDEMA.KALVISTA PHARMACEUTICALS INC - KVD001 DOES NOT MEET PRIMARY ENDPOINT.KALVISTA PHARMACEUTICALS INC - KVD001 GENERALLY SAFE AND WELL TOLERATED.KALVISTA PHARMACEUTICALS INC - PRE-PLANNED ANALYSES SHOW CLINICAL BENEFIT ON VISION.KALVISTA PHARMACEUTICALS INC - IN OVERALL STUDY POPULATION, KVD001 DEMONSTRATED A PROTECTION AGAINST VISION LOSS.  Full Article

Kalvista Pharmaceuticals Reports Qtrly Loss Per Share $0.42
Monday, 9 Sep 2019 

Sept 9 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS REPORTS FISCAL FIRST QUARTER RESULTS.PHASE 2 CLINICAL TRIAL OF KVD900 FOR ON-DEMAND ORAL TREATMENT OF HAE ATTACKS EXPECTED TO COMPLETE IN LATE 2019.KVD001 PHASE 2 CLINICAL TRIAL FOR PATIENTS WITH DIABETIC MACULAR EDEMA (DME) DATA EXPECTED IN Q4 2019.REVENUE WAS $3.4 MILLION FOR THREE MONTHS ENDED JULY 31, 2019, COMPARED TO $3.7 MILLION FOR SAME PERIOD IN 2018.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WERE $100.4 MILLION AS OF JULY 31, 2019.QTRLY LOSS PER SHARE $0.42.Q2 EARNINGS PER SHARE VIEW $-0.65, REVENUE VIEW $3.3 MILLION -- REFINITIV IBES DATA.  Full Article

Kalvista Pharmaceuticals Promotes Ben Palleiko To Chief Business Officer In Addition To Current Role As CFO
Wednesday, 27 Mar 2019 

March 27 (Reuters) - Kalvista Pharmaceuticals Inc ::KALVISTA PHARMACEUTICALS ANNOUNCES THE PROMOTION OF BENJAMIN L. PALLEIKO TO INCLUDE CHIEF BUSINESS OFFICER.KALVISTA PHARMACEUTICALS - PROMOTION OF BEN PALLEIKO TO CHIEF BUSINESS OFFICER IN ADDITION TO CURRENT ROLE AS CFO, EFFECTIVE IMMEDIATELY.  Full Article